Alnylam Pharmaceuticals is a biotechnology company focused on RNA interference (RNAi) medicines that silence disease-causing genes. It has brought multiple RNAi therapies to market for rare genetic and specialty diseases, including conditions such as hereditary ATTR amyloidosis and acute hepatic porphyria. The platform aims to expand into broader indications while building commercial capabilities in specialty markets. Physicians and patients with genetic or metabolic disorders form its primary clinical audience.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 773.7 | — | -72.2 | -202% |
| Q3 2025 | 1,249 | — | 251.1 | — |
| Q4 2025 | 1,097 | — | 186.4 | 2,308.9% |
| Q1 2026 | 1,167.2 | — | 206 | — |
| Q2 2026 | 1,291 | 66.9% | 164.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: GE HealthCare Technologies Inc. (GEHC), Biogen Inc. (BIIB), Willis Towers Watson Public Limited Company (WTW), Copart, Inc. (CPRT), Zscaler, Inc. (ZS), The Kraft Heinz Company (KHC)